Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycythemia Vera 3Thrombocythemia, Essential 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Brain Neoplasms 2Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Leukemia 1Glioma 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1

Interventions

blinatumomab 9Cyclophosphamide 7Rituximab 6Lenalidomide 6Dexamethasone 5Azacitidine 5venetoclax 4fludarabine 4Cytarabine 4fludarabine phosphate 3Maintenance 3Busulfan 3tislelizumab 2thymoglobulin 2pembrolizumab 2obinutuzumab 2daratumumab 2Whole-Body Irradiation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Melphalan 2Immunotherapy 2Imatinib Mesylate 2Drug Therapy 2Docetaxel 2Decitabine 2Clofarabine 2Cladribine 2Carboplatin 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm, Residual × peginterferon alfa-2a × Clear all
NCT01392170 2015-05-04

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡